Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Osteoporosis Reports
Erschienen in: Current Osteoporosis Reports 6/2019

20.11.2019 | Bone Marrow and Adipose Tissue (G Duque and B Lecka-Czernik, Section Editors)

Endogenous Glucocorticoid Signaling in the Regulation of Bone and Marrow Adiposity: Lessons from Metabolism and Cross Talk in Other Tissues

verfasst von: Anuj K. Sharma, Xingming Shi, Carlos M. Isales, Meghan E. McGee-Lawrence

Erschienen in: Current Osteoporosis Reports | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The development of adiposity in the bone marrow, known as marrow adipose tissue (MAT), is often associated with musculoskeletal frailty. Glucocorticoids, which are a key component of the biological response to stress, affect both bone and MAT. These molecules signal through receptors such as the glucocorticoid receptor (GR), but the role of the GR in regulation of MAT is not yet clear from previous studies. The purpose of this review is to establish and determine the role of GR-mediated signaling in marrow adiposity by comparing and contrasting what is known against other energy-storing tissues like adipose tissue, liver, and muscle, to provide better insight into the regulation of MAT during times of metabolic stress (e.g., dietary challenges, aging).

Recent Findings

GR-mediated glucocorticoid signaling is critical for proper storage and utilization of lipids in cells such as adipocytes and hepatocytes and proteolysis in muscle, impacting whole-body composition, energy utilization, and homeostasis through a complex network of tissue cross talk between these systems. Loss of GR signaling in bone promotes increased MAT and decreased bone mass.

Summary

GR-mediated signaling in the liver, adipose tissue, and muscle is critical for whole-body energy and metabolic homeostasis, and both similarities and differences in GR-mediated GC signaling in MAT as compared with these tissues are readily apparent. It is clear that GC-induced pathways work together through these tissues to affect systemic biology, and understanding the role of bone in these patterns of tissue cross talk may lead to a better understanding of MAT-bone biology that improves treatment strategies for frailty-associated diseases.
Literatur
1.
Hawkes CP, Mostoufi-Moab S. Fat-bone interaction within the bone marrow milieu: impact on hematopoiesis and systemic energy metabolism. Bone. 2019;119:57–64.PubMedCrossRef
2.
Sulston RJ, Cawthorn WP. Bone marrow adipose tissue as an endocrine organ: close to the bone? Horm Mol Biol Clin Invest. 2016;28:21–38.
3.
4.
Li J, Li J, Zuo B, Zhang L, Dai L, Zhang X. Osteoblast versus adipocyte: bone marrow microenvironment-guided epigenetic control. Case Rep Orthop Res. 2018;1:2–18.CrossRef
5.
Newton LA, Hanks JL, Davis M, Casazza K. The relationships among total body fat, bone mineral content and bone marrow adipose tissue in early-pubertal girls. Bonekey Rep. 2013;2:315.CrossRef
6.
Rharass T, and Lucas S (2018) Mechanisms in endocrinology: bone marrow adiposity and bone, a bad romance? Eur J Endocrinol
7.
Li T, Jiang S, Lu C, Yang W, Yang Z, Hu W, et al. Melatonin: another avenue for treating osteoporosis? J Pineal Res. 2019;66:e12548.PubMedCrossRef
8.
Yang S, Liu H, Liu Y, Liu L, Zhang W, and En L (2019) Effect of adiponectin secreted from adipose-derived stem cells on bone-fat balance and bone defect healing. J Tissue Eng Regen Med
9.
Manolagas SC, O’Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013;9:699–712.PubMedPubMedCentralCrossRef
10.
Zhang XZ, Kalu DN, Erbas B, Hopper JL, Seeman E. The effects of gonadectomy on bone size, mass, and volumetric density in growing rats are gender-, site-, and growth hormone-specific. J Bone Miner Res Off J Am Soc Bone Miner Res. 1999;14:802–9.CrossRef
11.
Bao T, Zeng L, Yang K, Li Y, Ren F, Zhang Y, et al. Can melatonin improve the osteopenia of perimenopausal and postmenopausal women? A meta-analysis. Int J Endocrinol. 2019;2019:5151678.PubMedPubMedCentralCrossRef
12.
Ikegame M, Hattori A, Tabata MJ, Kitamura KI, Tabuchi Y, Furusawa Y, et al. Melatonin is a potential drug for the prevention of bone loss during space flight. J Pineal Res. 2019;67:e12594.PubMedPubMedCentralCrossRef
13.
Fairfield H, Falank C, Harris E, Demambro V, McDonald M, Pettitt JA, et al. The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis. J Cell Physiol. 2018;233:1156–67.PubMedCrossRef
14.
Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359–404.PubMedCrossRef
15.
Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, et al. Brown adipose tissue activity controls triglyceride clearance. Nat Med. 2011;17:200–5.PubMedCrossRef
16.
Devlin MJ, Rosen CJ. The bone-fat interface: basic and clinical implications of marrow adiposity. Lancet Diabetes Endocrinol. 2015;3:141–7.PubMedCrossRef
17.
Hardouin P, Rharass T, Lucas S. Bone marrow adipose tissue: to be or not to be a typical adipose tissue? Front Endocrinol (Lausanne). 2016;7:85.CrossRef
18.
Ghali O, Al Rassy N, Hardouin P, Chauveau C. Increased bone marrow adiposity in a context of energy deficit: the tip of the iceberg? Front Endocrinol (Lausanne). 2016;7:125.CrossRef
19.
Scheller EL, Doucette CR, Learman BS, Cawthorn WP, Khandaker S, Schell B, et al. Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. Nat Commun. 2015;6:7808.PubMedPubMedCentralCrossRef
20.
Li Y, Meng Y, Yu X. The unique metabolic characteristics of bone marrow adipose tissue. Front Endocrinol (Lausanne). 2019;10:69.CrossRef
21.
Scheller EL, Cawthorn WP, Burr AA, Horowitz MC, MacDougald OA. Marrow adipose tissue: trimming the fat. Trends Endocrinol Metab. 2016;27:392–403.PubMedPubMedCentralCrossRef
22.
• Cawthorn WP, Scheller EL, Parlee SD, Pham HA, Learman BS, Redshaw CM, et al. Expansion of bone marrow adipose tissue during caloric restriction is associated with increased circulating glucocorticoids and not with hypoleptinemia. Endocrinology. 2016;157:508–21 This study provided some of the first evidence that GC may drive MAT expansion during caloric restriction. PubMedCrossRef
23.
Baek K, Bloomfield S. A. (2012) Blocking beta-adrenergic signaling attenuates reductions in circulating leptin, cancellous bone mass, and marrow adiposity seen with dietary energy restriction. J Appl Physiol. 1985;113:1792–801.CrossRef
24.
Hooshmand S, Balakrishnan A, Clark RM, Owen KQ, Koo SI, Arjmandi BH. Dietary l-carnitine supplementation improves bone mineral density by suppressing bone turnover in aged ovariectomized rats. Phytomedicine. 2008;15:595–601.PubMedCrossRef
25.
Adamek G, Felix R, Guenther HL, Fleisch H. Fatty acid oxidation in bone tissue and bone cells in culture. Characterization and hormonal influences. Biochem J. 1987;248:129–37.PubMedPubMedCentralCrossRef
26.
27.
Frey JL, Li Z, Ellis JM, Zhang Q, Farber CR, Aja S, et al. Wnt-Lrp5 signaling regulates fatty acid metabolism in the osteoblast. Mol Cell Biol. 2015;35:1979–91.PubMedPubMedCentralCrossRef
28.
Kim SP, Li Z, Zoch ML, Frey JL, Bowman CE, Kushwaha P, et al. Fatty acid oxidation by the osteoblast is required for normal bone acquisition in a sex- and diet-dependent manner. JCI Insight. 2017;2:92704.PubMedCrossRef
29.
30.
McGee-Lawrence ME, Carpio LR, Schulze RJ, Pierce JL, McNiven MA, Farr JN, et al. Hdac3 deficiency increases marrow adiposity and induces lipid storage and glucocorticoid metabolism in osteochondroprogenitor cells. J Bone Miner Res Off J Am Soc Bone Miner Res. 2016;31:116–28.CrossRef
31.
Gunaratnam K, Vidal C, Gimble JM, Duque G. Mechanisms of palmitate-induced lipotoxicity in human osteoblasts. Endocrinology. 2014;155:108–16.PubMedCrossRef
32.
Wei J, Ferron M, Clarke CJ, Hannun YA, Jiang H, Blaner WS, et al. Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. J Clin Invest. 2014;124:1–13.PubMedCrossRef
33.
Tommasini S, Nelson T, Faulkner-Filosa C, Rodeheffer MS, Rosen C, Lindskog D, and Horowitz M (2018) Selective deletion of marrow adipocytes leads to increased mesenchymal precursors, a shift in lineage allocation, and increased bone mass with improved bone biomechanics. In ASBMR Annual Meeting, American Society for Bone and Mineral Research, Montreal, Quebec, Canada
34.
Cao J, Ou G, Yang N, Ding K, Kream BE, Hamrick MW, et al. Impact of targeted PPARgamma disruption on bone remodeling. Mol Cell Endocrinol. 2015;410:27–34.PubMedPubMedCentralCrossRef
35.
Bermeo S, Al Saedi A, Vidal C, Khalil M, Pang M, Troen BR, et al. Treatment with an inhibitor of fatty acid synthase attenuates bone loss in ovariectomized mice. Bone. 2019;122:114–22.PubMedCrossRef
36.
Duque G, Li W, Vidal C, Bermeo S, Rivas D, Henderson J. Pharmacological inhibition of PPARgamma increases osteoblastogenesis and bone mass in male C57BL/6 mice. J Bone Miner Res Off J Am Soc Bone Miner Res. 2013;28:639–48.CrossRef
37.
Rosario R, Baban B, Hamrick M, Isales C, Shi X. PPARγ in inflammation and aging. Denver: In ASBMR Annual Meeting, American Society for Bone and Mineral Research; 2017.
38.
Rosario R, Ajith A, Ding K, Elsayed R, Su Y, Horuzsko A, et al. Complex role for PPARγ in bone, inflammation and immune function in aging animals. In: In ASBMR Annual Meeting. Montreal: American Society for Bone and Mineral Research; 2018.
39.
40.
41.
42.
Vande Berg BC, Malghem J, Lecouvet FE, Devogelaer JP, Maldague B, Houssiau FA. Fat conversion of femoral marrow in glucocorticoid-treated patients: a cross-sectional and longitudinal study with magnetic resonance imaging. Arthritis Rheum. 1999;42:1405–11.PubMedCrossRef
43.
Esche J, Shi L, Hartmann MF, Schonau E, Wudy SA, Remer T. Glucocorticoids and body fat inversely associate with bone marrow density of the distal radius in healthy youths. J Clin Endocrinol Metab. 2019;104:2250–6.PubMedCrossRef
44.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18:1319–28.PubMedCrossRef
45.
Hartmann K, Koenen M, Schauer S, Wittig-Blaich S, Ahmad M, Baschant U, et al. Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy. Physiol Rev. 2016;96:409–47.PubMedCrossRef
46.
Zhao ZY, Lu FH, Xie Y, Fu YR, Bogdan A, Touitou Y. Cortisol secretion in the elderly. Influence of age, sex and cardiovascular disease in a Chinese population. Steroids. 2003;68:551–5.PubMedCrossRef
47.
Johar H, Emeny RT, Bidlingmaier M, Reincke M, Thorand B, Peters A, et al. Blunted diurnal cortisol pattern is associated with frailty: a cross-sectional study of 745 participants aged 65 to 90 years. J Clin Endocrinol Metab. 2014;99:E464–8.PubMedCrossRef
48.
Reynolds RM, Dennison EM, Walker BR, Syddall HE, Wood PJ, Andrew R, et al. Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women. Calcif Tissue Int. 2005;77:134–8.PubMedCrossRef
49.
Henneicke H, Gasparini SJ, Brennan-Speranza TC, Zhou H, Seibel MJ. Glucocorticoids and bone: local effects and systemic implications. Trends Endocrinol Metab. 2014;25:197–211.PubMedCrossRef
50.
Hamrick MW, McGee-Lawrence ME, Frechette DM. Fatty infiltration of skeletal muscle: mechanisms and comparisons with bone marrow adiposity. Front Endocrinol (Lausanne). 2016;7:69.CrossRef
51.
Bauerle KT, Hutson I, Scheller EL, Harris CA. Glucocorticoid receptor signaling is not required for in vivo adipogenesis. Endocrinology. 2018;159:2050–61.PubMedPubMedCentralCrossRef
52.
Dalle H, Garcia M, Antoine B, Boehm V, Do TTH, Buyse M, et al. Adipocyte glucocorticoid receptor deficiency promotes adipose tissue expandability and improves the metabolic profile under corticosterone exposure. Diabetes. 2019;68:305–17.PubMedCrossRef
53.
• Mueller KM, Hartmann K, Kaltenecker D, Vettorazzi S, Bauer M, Mauser L, et al. Adipocyte glucocorticoid receptor deficiency attenuates aging- and HFD-induced obesity and impairs the feeding-fasting transition. Diabetes. 2017;66:272–86 This study demonstrates a key role for GR-mediated GC signaling in adipocyte lipolysis. PubMedCrossRef
54.
Desarzens S, Faresse N. Adipocyte glucocorticoid receptor has a minor contribution in adipose tissue growth. J Endocrinol. 2016;230:1–11.PubMedCrossRef
55.
Shen Y, Roh HC, Kumari M, Rosen ED. Adipocyte glucocorticoid receptor is important in lipolysis and insulin resistance due to exogenous steroids, but not insulin resistance caused by high fat feeding. Mol Metab. 2017;6:1150–60.PubMedPubMedCentralCrossRef
56.
Bose SK, Hutson I, Harris CA. Hepatic glucocorticoid receptor plays a greater role than adipose gr in metabolic syndrome despite renal compensation. Endocrinology. 2016;157:4943–60.PubMedPubMedCentralCrossRef
57.
Woods CP, Hazlehurst JM, Tomlinson JW. Glucocorticoids and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol. 2015;154:94–103.PubMedCrossRef
58.
John K, Marino JS, Sanchez ER, Hinds TD Jr. The glucocorticoid receptor: cause of or cure for obesity? Am J Physiol Endocrinol Metab. 2016;310:E249–57.PubMedCrossRef
59.
Tuttle LJ, Sinacore DR, Mueller MJ. Intermuscular adipose tissue is muscle specific and associated with poor functional performance. J Aging Res. 2012;2012:172957.PubMedPubMedCentralCrossRef
60.
Choi SJ, Files DC, Zhang T, Wang ZM, Messi ML, Gregory H, et al. Intramyocellular lipid and impaired myofiber contraction in normal weight and obese older adults. J Gerontol A Biol Sci Med Sci. 2016;71:557–64.PubMedCrossRef
61.
Reinders I, Murphy RA, Brouwer IA, Visser M, Launer L, Siggeirsdottir K, et al. Muscle quality and myosteatosis: novel associations with mortality risk: the Age, Gene/Environment Susceptibility (AGES)-Reykjavik study. Am J Epidemiol. 2016;183:53–60.PubMedCrossRef
62.
Khan IM, Perrard XY, Brunner G, Lui H, Sparks LM, Smith SR, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int J Obes. 2015;39:1607–18.CrossRef
63.
Addison O, Drummond MJ, LaStayo PC, Dibble LE, Wende AR, McClain DA, et al. Intramuscular fat and inflammation differ in older adults: the impact of frailty and inactivity. J Nutr Health Aging. 2014;18:532–8.PubMedPubMedCentralCrossRef
64.
Seelaender MC, Batista ML. Adipose tissue inflammation and cancer cachexia: the role of steroid hormones. Horm Mol Biol Clin Invest. 2014;17:5–12.
65.
Stephens NA, Skipworth RJ, Macdonald AJ, Greig CA, Ross JA, Fearon KC. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J Cachexia Sarcopenia Muscle. 2011;2:111–7.PubMedPubMedCentralCrossRef
66.
Morgan SA, Gathercole LL, Simonet C, Hassan-Smith ZK, Bujalska I, Guest P, et al. Regulation of lipid metabolism by glucocorticoids and 11beta-HSD1 in skeletal muscle. Endocrinology. 2013;154:2374–84.PubMedCrossRef
67.
Morgan SA, Hassan-Smith ZK, Doig CL, Sherlock M, Stewart PM, Lavery GG. Glucocorticoids and 11beta-HSD1 are major regulators of intramyocellular protein metabolism. J Endocrinol. 2016;229:277–86.PubMedPubMedCentralCrossRef
68.
Chu W, Wei W, Han H, Gao Y, Liu K, Tian Y, et al. Muscle-specific downregulation of GR levels inhibits adipogenesis in porcine intramuscular adipocyte tissue. Sci Rep. 2017;7:510.PubMedPubMedCentralCrossRef
69.
Shimizu N, Maruyama T, Yoshikawa N, Matsumiya R, Ma Y, Ito N, et al. A muscle-liver-fat signalling axis is essential for central control of adaptive adipose remodelling. Nat Commun. 2015;6:6693.PubMedCrossRef
70.
de Theije CC, Schols A, Lamers WH, Ceelen JJM, van Gorp RH, Hermans JJR, et al. Glucocorticoid receptor signaling impairs protein turnover regulation in hypoxia-induced muscle atrophy in male mice. Endocrinology. 2018;159:519–34.PubMedCrossRef
71.
Watson ML, Baehr LM, Reichardt HM, Tuckermann JP, Bodine SC, Furlow JD. A cell-autonomous role for the glucocorticoid receptor in skeletal muscle atrophy induced by systemic glucocorticoid exposure. Am J Physiol Endocrinol Metab. 2012;302:E1210–20.PubMedPubMedCentralCrossRef
72.
Hu Z, Wang H, Lee IH, Du J, Mitch WE. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J Clin Invest. 2009;119:3059–69.PubMedPubMedCentral
73.
Faught E, Vijayan MM. Loss of the glucocorticoid receptor in zebrafish improves muscle glucose availability and increases growth. Am J Physiol Endocrinol Metab. 2019;316:E1093–104.PubMedCrossRefPubMedCentral
74.
Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest. 2006;116:2152–60.PubMedPubMedCentralCrossRef
75.
Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010;11:517–31.PubMedCrossRef
76.
Rapp AE, Hachemi Y, Kemmler J, Koenen M, Tuckermann J, Ignatius A. Induced global deletion of glucocorticoid receptor impairs fracture healing. FASEB J: official publication of the Federation of American Societies for Experimental Biology. 2018;32:2235–45.CrossRef
77.
•• Pierce JL, Ding KH, Xu J, Sharma AK, Yu K, Del Mazo Arbona N, Rodriguez-Santos Z, Bernard P, Bollag WB, Johnson MH, Hamrick MW, Begun DL, Shi XM, Isales CM, and McGee-Lawrence ME (2019) The glucocorticoid receptor in osteoprogenitors regulates bone mass and marrow fat. J Endocrinol. This study was the first to show that loss of the GR in bone promoted increased MAT deposition.
78.
Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268–75.PubMedCrossRef
79.
Fumoto T, Ishii KA, Ito M, Berger S, Schutz G, Ikeda K. Mineralocorticoid receptor function in bone metabolism and its role in glucocorticoid-induced osteopenia. Biochem Biophys Res Commun. 2014;447:407–12.PubMedCrossRef
80.
Hinds TD Jr, Ramakrishnan S, Cash HA, Stechschulte LA, Heinrich G, Najjar SM, et al. Discovery of glucocorticoid receptor-beta in mice with a role in metabolism. Mol Endocrinol. 2010;24:1715–27.PubMedPubMedCentralCrossRef
81.
Oakley RH, Cidlowski JA. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol. 2013;132:1033–44.PubMedPubMedCentralCrossRef
82.
Beavan S, Horner A, Bord S, Ireland D, Compston J. Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J Bone Miner Res Off J Am Soc Bone Miner Res. 2001;16:1496–504.CrossRef
Metadaten
Titel
Endogenous Glucocorticoid Signaling in the Regulation of Bone and Marrow Adiposity: Lessons from Metabolism and Cross Talk in Other Tissues
verfasst von
Anuj K. Sharma
Xingming Shi
Carlos M. Isales
Meghan E. McGee-Lawrence
Publikationsdatum
20.11.2019
Verlag
Springer US
Erschienen in
Current Osteoporosis Reports / Ausgabe 6/2019
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-019-00554-6

Weitere Artikel der Ausgabe 6/2019

Current Osteoporosis Reports 6/2019 Zur Ausgabe

Quality of Care in Osteoporosis (S Silverman and J Curtis, Section Editors)

Pragmatic Clinical Trials in Osteoporosis

Skeletal Biology and Regulation (M Forwood and A Robling, Section Editors)

Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) Drives Activation of Bone Remodelling and Skeletal Metastasis

Osteocytes (J Klein-Nulend, Section editor)

Aging and Mechanoadaptive Responsiveness of Bone

Bone Marrow and Adipose Tissue (G Duque and B Lecka-Czernik, Section Editors)

Bone Marrow Adipose Tissue Quantification by Imaging

Quality of Care in Osteoporosis (S Silverman and J Curtis, Section Editors)

Bone Health TeleECHO: a Force Multiplier to Improve the Care of Skeletal Diseases in Underserved Communities

Bone Marrow and Adipose Tissue (G Duque and B Lecka-Czernik, Section Editors)

Insulin Signaling in Bone Marrow Adipocytes

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

16.04.2024 | Spondylitis ankylosans | Nachrichten

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

15.04.2024 | Knie-TEP | Nachrichten

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

11.04.2024 | Spondyloarthritiden | Nachrichten

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA
weitere anzeigen

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise